Alzheimer’s Disease (AD) is a common neurological disorder that af fects the nerve cells in the brain (1). An atomically guided PET reconstruction (AGR) has been a promising method to improve the quality of amyloid PET images (6,7). While previous studies investigated the AGR method on PET images, it’s unclear whether the AGR method improves PET image contrast (7). This study aimed to determine the influence of AGR on the diagnostic quality of Amyloid PET images for AD.

A dataset of 76 volunteers aged 50-87 years old from imaging records from NYU Langone Radiology in Manhattan, NY was investigated. There were no statistically significant differences between the AGR and non-AGR standard uptake value ratios (SUVrs) (Whole Temporal Lobe: p=0.94272; Whole Superior Frontal: p=0.91928; Whole Precuneus: p=0.98383; Whole Hippocampus: p=0.98383; Whole Lateral Occipital Lobe: p=0.98677). These results suggest that the AGR method did not improve the diagnostic quality of the PET image for AD. Future studies should focus on alternative PET image metrics when applying the AGR method to better understand how the AGR method af fects the diagnostic quality of the PET image for AD. Keywords: Alzheimer’s Disease (AD), PET imaging, neuroradiology, amyloid-beta protein plaque, amyloid PET scan.

References

• Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules(Basel, Switzerland), 25(24), 5789. https://doi.org/10.3390/molecules25245789
• Ma, C., Hong, F ., & Yang, S. (2022). Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules (Basel, Switzerland), 27(4), 1210. https://doi.org/10.3390/molecules27041210
• Rong, J., Haider, A., Jeppesen, T. E., et al. (2023). Radiochemistry for positron emission tomography. Nature Communications, 14, 3257. https://doi.org/10.1038/s41467-023-36377-4
• Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D., & Rabinovici, G. D. (2022). The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. Journal of nuclear medicine: official publication, Society of Nuclear Medicine, 63(Suppl 1), 13S–19S. https://doi.org/10.2967/jnumed.121.2631955
• Bollack, A., Pemberton, H. G., Collij, L. E., Markiewicz, P., Cash, D. M., Farrar, G., Barkhof, F., & on behalf on the AMYPAD consortium (2023). Longitudinal amyloid and tau PET imaging in Alzheimer’s disease: A systematic review of methodologies and factors affecting quantification. Alzheimer’s & dementia: The Journal of the Alzheimer’s Association, 19(11), 5232–5252. https://doi.org/10.1002/alz.13158
• Yang, B., Gong, K., Liu, H., Li, Q., & Zhu, W . (2024). Anatomically Guided PET Image Reconstruction Using Conditional Weakly-Supervised Multi-Task Learning Integrating Self-Attention. IEEE transactions on medical imaging, 43(6), 2098–2112. https://doi.org/10.1109/TMI.2024.3356189
• Schramm, G., Rigie, D., Vahle, T ., Rezaei, A., Van Laere, K., Shepherd, T ., Nuyts, J., & Boada, F . (2021). Approximating anatomically-guided PET reconstruction in image space using a convolutional neural network. Neu roImage, 224, 117399. https://doi.org/10.1016/j.neuroim age.2020.117399
• Hashimoto, F ., Onishi, Y ., Ote, K. et al. Deep learning-based PET image denoising and reconstruction: a review. RadiolPhys Technol 17, 24–46 (2024). https://doi.org/10.1007/s12194-024-00780-3
• Chowdhury, S., & Chowdhury, N. S. (2023). Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review. International journal of immunopathology and pharmacology, 37, 3946320231209839. https://doi.org/10.1177/03946320231209839
• Krishnadas, N., Villemagne, V . L., Doré, V ., & Rowe, C. C. (2021). Advances in Brain Amyloid Imaging. Sem inars in nuclear medicine, 51(3), 241–252. https://doi.org/10.1053/j.semnuclmed.2020.12.005
• Zivari-Ghader, T., Valioglu, F., Eftekhari, A., Aliyeva, I., Beylerli, O., Davran, S., Cho, W. C., Beilerli, A., Khalilov, R., & Javadov, S. (2024). Recent progresses in natural based therapeutic materials for Alzheimer’s disease. He liyon, 10(2), Article e26351. https://doi.org/10.1016/j.heli yon.2024.e26351
• Bhole, R. P., Chikhale, R. V., & Rathi, K. M. (2023). Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives. IBRO neuroscience reports, 16, 8–42. https://doi.org/10.1016/j. ibneur.2023.11.003
• Hampel, H., Hardy, J., Blennow, K., & et al. (2021). mer’s disease: a multicenter study. Annals of Nuclear Medicine, 36(12), 1039–1049. https://doi.org/10.1007/s12149-022-01792-y
• Alban, S. L., Lynch, K. M., Ringman, J. M., Toga, A. W., Chui, H. C., Sepehrband, F., Choupan, J., & Alzheimer’s Disease Neuroimaging Initiative (2023). The association between white matter hyperintensities and amyloid and tau deposition. NeuroImage. Clinical, 38, 103383. 15. Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sa bri, O., Teipel, S. J., & Alzheimer’s Disease Neuroimaging Initiative (2017). In vivo staging of regional amyloid deposition. Neurology, 89(20), 2031–2038. https://doi.org/10.1212/WNL.0000000000004643
• Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019). Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA neurology, 76(11), 1319–1329. https://doi.org/10.1001/jamaneurol.2019.2214